50 results on '"Melamed, Isaac"'
Search Results
2. BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children
3. Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study
4. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency
5. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America
6. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
7. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease
8. Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease
9. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
10. Mast cells, brain inflammation and autism
11. Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.
12. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency
13. Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
14. Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency
15. Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease
16. Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
17. Carimune NF Liquid is a Safe and Effective Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency Diseases
18. Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency
19. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients
20. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency
21. Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm]).
22. Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome.
23. Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study.
24. PERSISTENT CAMPYLOBACTERIOSIS IN AN IMMUNE DEFICIENT CHILD
25. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
26. Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases.
27. Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study.
28. A pilot study of high‐dose intravenous immunoglobulin 5% for autism: Impact on autism spectrum and markers of neuroinflammation.
29. Subcutaneous Immunoglobulin 16.5% (Cutaquig) is Safe and Efficacious at Modified Dosing Regimens in Patients With Primary Immunodeficiency Disease.
30. Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.
31. Subcutaneous Immunoglobulins: Product Characteristics and Their Role in Primary Immunodeficiency Disease.
32. Benefit of Ketotifen in Patients with Eosinophilic Gastroenteritis.
33. Nerve growth factor signal transduction in human B lymphocytes is mediated by gp140.
34. Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies.
35. Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin 16.5% Administered at Modified Dosing Regimens in Patients with Primary Immunodeficiency Diseases – Study Design.
36. Long-term adverse events, efficacy, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin in patients aged < 18 years with primary immunodeficiency diseases.
37. Local adverse reaction rates decreased over time during treatment with recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin G (fSCIG) in patients with primary immunodeficiency diseases in the fSCIG phase 3 studies.
38. Neurologic manifestations of hereditary angioedema.
39. Observational Study to Determine the Tolerability of Intravenous Immunoglobulin 5% for the Treatment of Patients Diagnosed with Primary Immunodeficiency Disorders.
40. A new subset of common variable immune deficiency characterized by reduced C1 esterase inhibitor levels.
41. Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs).
42. Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive Studies.
43. Attention Deficit Disorder and Allergic Rhinitis: Are They Related?
44. Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America.
45. Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies.
46. Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (rHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs).
47. Coffee and the immune system
48. Benefit of oral immune globulin therapy in patients with immunodeficiency and chronic diarrhea
49. Severe systemic immune response syndrome, low plasma paraoxonase activity, and a new albumin species in a traumatized patient with Gaucher's disease
50. Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes in patient symptoms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.